EntryPoint Capital’s Utah Medical Products UTMD Stock Holding History

EntryPoint Capital’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,321	Closed	-$222K	–	978
2024 Q3	$222K	Buy	+3,321	New	+$225K	0.13%	401
2024 Q2	–	Sell	-3,240	Closed	-$230K	–	1648
2024 Q1	$230K	Buy	3,240 +1,794	+124%	+$135K	0.21%	72
2023 Q4	$122K	Buy	+1,446	New	+$120K	0.12%	277

Other funds holding UTMD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EntryPoint Capital's UTMD Position: Q4 2024 in Review

EntryPoint Capital sold out of Utah Medical Products (UTMD) in Q4 2024, closing a stake of 3,321 shares — an estimated $222K sold.

EntryPoint Capital first reported a position in UTMD in Q4 2023 and held it in 3 quarters. The position peaked at $230K in Q1 2024. 112 funds tracked by Wall St. Rank hold UTMD as of Q4 2024.

EntryPoint Capital reported no remaining Utah Medical Products position as of Q4 2024 after selling out during the quarter.
EntryPoint Capital sold 3,321 Utah Medical Products shares in Q4 2024, an estimated $222K.
EntryPoint Capital first reported a position in Utah Medical Products in Q4 2023 and held it in 3 quarters.
EntryPoint Capital's Utah Medical Products position peaked at $230K in Q1 2024.
112 funds tracked by Wall St. Rank held Utah Medical Products as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.